www.breastlink.com Summarizes Multigenerational Study: Oral Contraceptive Use Increases Breast Cancer Risk For Close Blood Relatives of Women Breast Cancer Patients

www.breastlink.com Recognizes April as National Cancer Control Month



Apr 26, 2001, 01:00 ET from Breast Cancer Care & Research Fund

    TORRANCE, Calif., April 26 /PRNewswire/ -- The Breast Cancer Care &
 Research Fund's web site, www.breastlink.com, reviews four medical journal
 articles this month as an educational tribute to National Cancer Control Month
 -- one of which provides an analysis of follow-up medical information about
 women relatives and descendants of breast cancer patients who participated in
 a large study conducted during the l940s which revealed that close blood
 relatives who had ever used oral contraceptives up to l975 were more likely to
 have breast cancer than their counterparts who had never used oral
 contraceptives.
     Biologist and medical writer Jane Babbitt, provides the analysis this
 month of the study by researchers at Johns Hopkins University School of
 Medicine.  "This study by researchers from the Mayo Clinic and the University
 of Minnesota is not only unique but particularly interesting because it
 followed the incidence of breast cancer through several generations of women
 related to breast cancer patients who were diagnosed before the marketing of
 oral contraceptives (OCs).  In this context of family history of breast
 cancer, the researchers sought to determine whether OC use by women relatives
 had increased their risk of developing cancer."
     She adds, "This question is especially relevant because OC use has been
 recommended as a means of reducing ovarian cancer risk in women who carry
 breast cancer related genetic mutations in BRCA1 or BRCA2."  BRCA1 and BRCA2
 are two genetic alterations frequently associated with breast and ovarian
 cancer.
     Beth Karlan, MD, provided the expert commentary.  An expert commentary
 accompanies every analysis on the www.breastlink.com web site.  Dr. Karlan is
 Director, Division of Gynecologic Oncology, and Director, The Gilda Radner
 Ovarian Cancer Detection Program at Cedars-Sinai Medical Center, and Associate
 Professor, Obstetrics and Gynecology, Associate Director, Women's Cancer
 Program, Jonsson Comprehensive Cancer Center, University California, Los
 Angeles (UCLA).
     Dr. Karlan says the take-home message from this study really should be
 that, "These authors are responsible and sage clinical investigators who don't
 want to be alarmist with their results.  The data suggest a possible link
 between oral contraceptive pill use and breast cancer in women with a family
 history of the disease.  However, there is the question of the relevance of
 these results for women in 2001 when the estrogen dose in birth control pills
 is less than 20 percent of what it was for the majority of the women who are
 the focus of the study."
     Adds Dr. Karlan, "After l975, the study group was still using
 predominantly 50-microgram pills.  Also there were only two breast cancer
 cases among the 60 women that had a first degree relative with breast cancer
 in this group, so I don't think we can reach any real conclusions about these
 women yet.  In addition while the data suggest a possible link, there was no
 dose response seen, i.e., there was no relation between degree of risk and
 hormone dose."
     Breastlink.com's team of award-winning professional medical writers
 monthly review scientific articles published in peer-reviewed journals, and in
 turn, publish their analyses in language that nonscientists can understand.
 The reviews are provided in both English and Spanish.
     John Link, MD, Chairman of the Board and Founder of the nonprofit
 organization, The Breast Cancer Care & Research Fund, says, "Since we started
 providing monthly reviews online last year [(April 2000)], we have received a
 tremendously positive response to our interpretation/translation of medical
 journal studies.  The site's contents help readers become scientifically
 literate by teaching them to question what they read and hear and to consult
 primary sources."  Dr. Link is the author of "The Breast Cancer Survival
 Manual" -- a step-by-step guide for the woman with newly diagnosed breast
 cancer.
     He adds, "The new 'science behind the news' web site, www.breastlink.com,
 is currently preparing for an official launch slated for Mother's Day, Sunday,
 May l3, 2001.  Our site provides reliable, in-depth, unbiased analysis of
 leading-edge research and information regarding innovations in breast cancer
 treatment.  Our education is comprehensive -- we make it easy for readers to
 understand through an interactive, pop-up glossary of terms; we provide a
 sidebar detailing 'how to read scientific journals'; and the site provides an
 easily searchable database, which already contains -- nearly 60 reviews
 archived for quick retrieval."  Reviews may be downloaded free of charge
 Breastlink.com is supported totally by a nonprofit organization.  Consumer
 privacy is ensured, as the site does not collect information or require
 registration to enter or navigate.
 
     For more information on oral contraceptives and cancer and other reviews,
 see www.breastlink.com, or contact The Breast Cancer Care & Research Fund,
 Mary Batten, Editor-in-Chief, 23430 Hawthorne Blvd., Suite 350, Torrance, CA,
 90505, 310.791.6295.
 
                      MAKE YOUR OPINION COUNT - Click Here
                http://tbutton.prnewswire.com/prn/11690X29839372
 
 

SOURCE Breast Cancer Care & Research Fund
    TORRANCE, Calif., April 26 /PRNewswire/ -- The Breast Cancer Care &
 Research Fund's web site, www.breastlink.com, reviews four medical journal
 articles this month as an educational tribute to National Cancer Control Month
 -- one of which provides an analysis of follow-up medical information about
 women relatives and descendants of breast cancer patients who participated in
 a large study conducted during the l940s which revealed that close blood
 relatives who had ever used oral contraceptives up to l975 were more likely to
 have breast cancer than their counterparts who had never used oral
 contraceptives.
     Biologist and medical writer Jane Babbitt, provides the analysis this
 month of the study by researchers at Johns Hopkins University School of
 Medicine.  "This study by researchers from the Mayo Clinic and the University
 of Minnesota is not only unique but particularly interesting because it
 followed the incidence of breast cancer through several generations of women
 related to breast cancer patients who were diagnosed before the marketing of
 oral contraceptives (OCs).  In this context of family history of breast
 cancer, the researchers sought to determine whether OC use by women relatives
 had increased their risk of developing cancer."
     She adds, "This question is especially relevant because OC use has been
 recommended as a means of reducing ovarian cancer risk in women who carry
 breast cancer related genetic mutations in BRCA1 or BRCA2."  BRCA1 and BRCA2
 are two genetic alterations frequently associated with breast and ovarian
 cancer.
     Beth Karlan, MD, provided the expert commentary.  An expert commentary
 accompanies every analysis on the www.breastlink.com web site.  Dr. Karlan is
 Director, Division of Gynecologic Oncology, and Director, The Gilda Radner
 Ovarian Cancer Detection Program at Cedars-Sinai Medical Center, and Associate
 Professor, Obstetrics and Gynecology, Associate Director, Women's Cancer
 Program, Jonsson Comprehensive Cancer Center, University California, Los
 Angeles (UCLA).
     Dr. Karlan says the take-home message from this study really should be
 that, "These authors are responsible and sage clinical investigators who don't
 want to be alarmist with their results.  The data suggest a possible link
 between oral contraceptive pill use and breast cancer in women with a family
 history of the disease.  However, there is the question of the relevance of
 these results for women in 2001 when the estrogen dose in birth control pills
 is less than 20 percent of what it was for the majority of the women who are
 the focus of the study."
     Adds Dr. Karlan, "After l975, the study group was still using
 predominantly 50-microgram pills.  Also there were only two breast cancer
 cases among the 60 women that had a first degree relative with breast cancer
 in this group, so I don't think we can reach any real conclusions about these
 women yet.  In addition while the data suggest a possible link, there was no
 dose response seen, i.e., there was no relation between degree of risk and
 hormone dose."
     Breastlink.com's team of award-winning professional medical writers
 monthly review scientific articles published in peer-reviewed journals, and in
 turn, publish their analyses in language that nonscientists can understand.
 The reviews are provided in both English and Spanish.
     John Link, MD, Chairman of the Board and Founder of the nonprofit
 organization, The Breast Cancer Care & Research Fund, says, "Since we started
 providing monthly reviews online last year [(April 2000)], we have received a
 tremendously positive response to our interpretation/translation of medical
 journal studies.  The site's contents help readers become scientifically
 literate by teaching them to question what they read and hear and to consult
 primary sources."  Dr. Link is the author of "The Breast Cancer Survival
 Manual" -- a step-by-step guide for the woman with newly diagnosed breast
 cancer.
     He adds, "The new 'science behind the news' web site, www.breastlink.com,
 is currently preparing for an official launch slated for Mother's Day, Sunday,
 May l3, 2001.  Our site provides reliable, in-depth, unbiased analysis of
 leading-edge research and information regarding innovations in breast cancer
 treatment.  Our education is comprehensive -- we make it easy for readers to
 understand through an interactive, pop-up glossary of terms; we provide a
 sidebar detailing 'how to read scientific journals'; and the site provides an
 easily searchable database, which already contains -- nearly 60 reviews
 archived for quick retrieval."  Reviews may be downloaded free of charge
 Breastlink.com is supported totally by a nonprofit organization.  Consumer
 privacy is ensured, as the site does not collect information or require
 registration to enter or navigate.
 
     For more information on oral contraceptives and cancer and other reviews,
 see www.breastlink.com, or contact The Breast Cancer Care & Research Fund,
 Mary Batten, Editor-in-Chief, 23430 Hawthorne Blvd., Suite 350, Torrance, CA,
 90505, 310.791.6295.
 
                      MAKE YOUR OPINION COUNT - Click Here
                http://tbutton.prnewswire.com/prn/11690X29839372
 
 SOURCE  Breast Cancer Care & Research Fund